Monday - June 9, 2025

LOGIN  |  REGISTER
Amneal Pharmaceuticals

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 450.50
6.68 1.51
925,540
257.53M
US$ 116.020B
US$ 493.22
10.15 2.10
1.36M
108.07M
US$ 53.300B
US$ 300.83
-7.17 -2.33
912,087
128.98M
US$ 38.800B
US$ 585.93
5.34 0.92
203,624
59.80M
US$ 35.040B
US$ 108.49
-1.66 -1.51
1.13M
239.74M
US$ 26.010B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 20.59
0.86 4.36
3.90M
737.45M
US$ 15.180B
US$ 33.78
0.03 0.09
2.52M
444.30M
US$ 15.010B
US$ 325.82
6.11 1.91
435,641
44.64M
US$ 14.540B
US$ 22.20
0.39 1.79
954,363
635.24M
US$ 14.100B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 68.77
1.53 2.28
1.62M
192.65M
US$ 13.250B
US$ 73.62
0.88 1.21
1.52M
178.90M
US$ 13.170B
US$ 125.39
0.78 0.63
832,008
101.25M
US$ 12.700B
US$ 43.03
0.66 1.56
2.32M
285.58M
US$ 12.290B
US$ 56.65
1.38 2.50
2.08M
190.58M
US$ 10.800B
US$ 27.46
1.34 5.13
8.38M
384.82M
US$ 10.570B
US$ 173.06
-4.49 -2.53
583,500
59.81M
US$ 10.350B
US$ 11.23
0.03 0.27
4.87M
727.95M
US$ 8.170B
US$ 127.60
-0.30 -0.23
3.05M
63.53M
US$ 8.110B
US$ 48.69
0.38 0.79
1.16M
158.89M
US$ 7.740B
US$ 40.65
2.24 5.83
702,660
186.89M
US$ 7.600B
US$ 41.09
0.89 2.21
1.24M
184.80M
US$ 7.590B
US$ 38.62
0.28 0.73
2.40M
188.99M
US$ 7.300B
US$ 69.60
0.59 0.85
956,922
104.78M
US$ 7.290B
US$ 54.25
0.70 1.31
1.27M
127.23M
US$ 6.900B
US$ 84.34
-1.20 -1.40
1.74M
81.83M
US$ 6.900B
US$ 111.13
2.33 2.14
697,388
60.45M
US$ 6.720B
US$ 35.00
3.52 11.18
4.17M
183.45M
US$ 6.420B
US$ 40.06
0.76 1.93
2.09M
155.66M
US$ 6.240B
US$ 278.23
4.13 1.51
267,350
21.81M
US$ 6.070B
US$ 35.29
0.05 0.14
1.14M
157.90M
US$ 5.570B
US$ 111.91
1.25 1.13
623,697
48.46M
US$ 5.420B
US$ 12.72
0.87 7.34
141,139
411.34M
US$ 5.230B
US$ 31.71
0.71 2.29
1.08M
161.80M
US$ 5.130B
US$ 78.02
-0.07 -0.09
508,115
65.62M
US$ 5.120B
US$ 20.61
0.67 3.36
1.32M
236.39M
US$ 4.870B
US$ 36.99
2.19 6.29
1.54M
124.64M
US$ 4.610B
US$ 36.24
0.65 1.83
1.47M
119.31M
US$ 4.320B
US$ 68.11
1.93 2.92
700,933
61.46M
US$ 4.190B
US$ 38.11
1.57 4.30
991,421
108.94M
US$ 4.150B
US$ 43.19
3.98 10.15
4.80M
95.52M
US$ 4.130B
US$ 27.03
0.52 1.96
880,403
149.57M
US$ 4.040B
US$ 136.94
4.32 3.26
259,653
28.76M
US$ 3.940B
US$ 56.21
0.20 0.36
760,758
68.46M
US$ 3.850B
US$ 32.30
0.22 0.69
725,511
118.01M
US$ 3.810B
US$ 54.28
0.34 0.63
1.38M
69.80M
US$ 3.790B
US$ 12.76
1.30 11.34
392,183
292.16M
US$ 3.730B
US$ 68.10
1.85 2.79
563,005
54.07M
US$ 3.680B
US$ 21.98
0.64 3.00
1.22M
166.39M
US$ 3.660B
US$ 41.86
3.29 8.53
4.67M
85.35M
US$ 3.570B
US$ 46.80
0.00 0.00
3.11M
74.39M
US$ 3.480B
US$ 37.17
0.26 0.70
925,276
92.34M
US$ 3.430B
US$ 75.51
0.29 0.39
587,998
43.12M
US$ 3.260B
US$ 54.38
0.56 1.04
1.06M
59.60M
US$ 3.240B
US$ 10.66
0.16 1.52
172,037
301.94M
US$ 3.220B
US$ 34.23
-0.02 -0.06
1.55M
93.62M
US$ 3.200B
US$ 25.87
0.51 2.01
1.18M
119.27M
US$ 3.090B
US$ 47.62
-0.04 -0.08
971,337
64.77M
US$ 3.080B
US$ 33.01
0.69 2.13
462,943
92.74M
US$ 3.060B
US$ 46.88
-1.95 -3.99
875,960
63.06M
US$ 2.960B
US$ 16.77
0.75 4.68
2.16M
169.28M
US$ 2.840B
US$ 31.64
0.91 2.96
564,875
76.24M
US$ 2.410B
US$ 19.28
0.18 0.94
1.39M
124.39M
US$ 2.400B
US$ 3.16
0.26 8.97
18.75M
730.16M
US$ 2.310B
US$ 11.04
0.06 0.55
4.05M
207.13M
US$ 2.290B
US$ 46.38
1.73 3.87
265,391
48.00M
US$ 2.230B
US$ 20.14
0.63 3.23
978,997
107.05M
US$ 2.160B
US$ 43.30
-0.10 -0.23
229,642
49.36M
US$ 2.140B
US$ 27.46
0.48 1.78
968,286
77.50M
US$ 2.130B
US$ 14.70
0.48 3.38
1.75M
143.92M
US$ 2.120B
US$ 16.81
0.35 2.13
1.20M
124.43M
US$ 2.090B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 26.91
0.28 1.05
991,770
76.13M
US$ 2.050B
US$ 35.60
0.57 1.63
432,969
57.03M
US$ 2.030B
US$ 105.99
1.81 1.74
89,948
18.90M
US$ 2.000B
US$ 34.33
0.75 2.23
364,016
57.03M
US$ 1.960B
US$ 21.73
0.63 2.99
771,037
86.43M
US$ 1.880B
US$ 37.25
-0.66 -1.74
973,183
50.03M
US$ 1.860B
US$ 59.68
-4.54 -7.07
84,892
30.88M
US$ 1.840B
US$ 6.16
0.20 3.36
5.09M
298.81M
US$ 1.840B
US$ 27.73
-0.24 -0.86
416,491
65.90M
US$ 1.830B
US$ 40.98
3.33 8.84
1.11M
43.42M
US$ 1.780B
US$ 17.03
0.83 5.12
1.26M
101.12M
US$ 1.720B
US$ 14.37
0.86 6.37
2.40M
117.04M
US$ 1.680B
US$ 43.92
-0.16 -0.36
614,262
38.23M
US$ 1.680B
US$ 24.28
-1.05 -4.15
247,714
65.46M
US$ 1.590B
US$ 11.92
0.06 0.51
1.02M
131.84M
US$ 1.570B
US$ 18.58
1.57 9.24
3.84M
82.81M
US$ 1.540B
US$ 26.21
1.45 5.86
804,873
58.63M
US$ 1.540B
US$ 18.14
0.12 0.67
1.33M
84.64M
US$ 1.540B
US$ 17.20
0.54 3.24
462,722
88.07M
US$ 1.510B
US$ 14.70
0.71 5.08
2.57M
101.77M
US$ 1.500B
US$ 10.09
0.22 2.23
1.05M
147.58M
US$ 1.490B
US$ 50.02
2.01 4.19
218,021
29.76M
US$ 1.490B
US$ 15.24
0.42 2.83
1.16M
94.69M
US$ 1.440B
US$ 22.60
-8.03 -26.22
12.63M
63.32M
US$ 1.430B
US$ 21.35
1.82 9.32
836,693
66.34M
US$ 1.420B
US$ 9.02
0.56 6.62
2.12M
157.22M
US$ 1.420B
US$ 8.23
1.09 15.27
122,425
170.74M
US$ 1.410B
US$ 14.49
1.05 7.81
1.26M
97.19M
US$ 1.410B
US$ 11.79
0.18 1.55
142,346
115.65M
US$ 1.360B
US$ 10.24
0.29 2.91
1.37M
131.46M
US$ 1.350B
US$ 21.58
0.41 1.94
1.02M
62.60M
US$ 1.350B
US$ 15.32
0.60 4.08
1.68M
87.03M
US$ 1.330B
US$ 10.25
0.29 2.91
1.52M
117.58M
US$ 1.210B
US$ 4.38
0.08 1.86
1.53M
275.78M
US$ 1.210B
US$ 21.13
-0.34 -1.58
1.05M
57.26M
US$ 1.210B
US$ 7.45
0.46 6.58
7.33M
160.18M
US$ 1.190B
US$ 8.19
0.10 1.24
895,821
143.18M
US$ 1.170B
US$ 14.68
0.44 3.09
391,369
79.21M
US$ 1.160B
US$ 7.22
0.47 6.96
1.33M
152.52M
US$ 1.100B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 16.97
0.35 2.11
297,691
59.80M
US$ 1.010B
US$ 20.74
-0.63 -2.95
663,247
48.86M
US$ 1.010B
US$ 4.41
-0.05 -1.12
307,666
224.34M
US$ 989.340M
US$ 11.45
0.29 2.60
1.30M
85.36M
US$ 977.370M
US$ 1.60
0.04 2.56
8.70M
604.50M
US$ 967.200M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 17.27
0.66 3.97
1.77M
53.44M
US$ 922.910M
US$ 9.97
0.34 3.53
722,880
91.51M
US$ 912.350M
US$ 16.78
0.73 4.55
82,309
54.23M
US$ 909.980M
US$ 12.78
0.28 2.24
1.03M
70.84M
US$ 905.340M
US$ 31.96
1.66 5.48
475,012
27.50M
US$ 878.900M
US$ 3.68
0.04 1.10
6.83M
236.85M
US$ 871.610M
US$ 12.60
0.47 3.87
341,754
68.88M
US$ 867.890M
US$ 3.97
0.28 7.59
8.16M
218.18M
US$ 866.170M
US$ 2.58
0.10 4.03
4.94M
335.57M
US$ 865.770M
US$ 13.98
0.80 6.07
2.50M
60.68M
US$ 848.310M
US$ 19.92
0.36 1.84
42,695
41.94M
US$ 835.440M
US$ 44.56
2.30 5.44
440,814
18.64M
US$ 830.600M
US$ 8.09
0.51 6.73
7.12M
101.85M
US$ 823.970M
US$ 11.86
0.65 5.80
2,075
67.84M
US$ 804.450M
US$ 16.12
0.50 3.20
390,237
49.77M
US$ 802.290M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 10.38
0.63 6.46
1.90M
76.96M
US$ 798.840M
US$ 23.52
0.05 0.21
216,798
33.70M
US$ 792.620M
US$ 5.74
0.47 8.92
1.00M
133.17M
US$ 764.400M
US$ 6.80
0.81 13.52
2.70M
110.46M
US$ 751.130M
US$ 5.45
0.30 5.83
1.32M
137.72M
US$ 750.570M
US$ 4.30
0.60 16.22
269,055
170.55M
US$ 733.360M
US$ 5.97
0.18 3.11
669,350
121.55M
US$ 725.650M
US$ 7.19
0.24 3.45
1.43M
100.85M
US$ 725.110M
US$ 8.41
0.44 5.52
157,569
85.82M
US$ 721.750M
US$ 23.70
2.56 12.11
672,454
30.43M
US$ 721.190M
US$ 2.44
0.07 2.95
3.80M
295.37M
US$ 720.700M
US$ 14.37
0.56 4.06
536,919
49.42M
US$ 709.920M
US$ 8.27
0.49 6.30
1.18M
84.82M
US$ 701.460M
US$ 4.58
0.12 2.69
1.81M
149.08M
US$ 682.790M
US$ 9.65
0.53 5.81
507,754
69.98M
US$ 675.310M
US$ 3.48
0.08 2.35
523,196
189.49M
US$ 659.430M
US$ 9.32
0.16 1.75
1.36M
70.57M
US$ 657.710M
US$ 12.50
-0.11 -0.87
167,578
52.03M
US$ 650.380M
US$ 14.23
1.05 7.97
2.49M
45.47M
US$ 647.040M
US$ 2.84
0.29 11.37
5.88M
223.27M
US$ 634.090M
US$ 7.08
0.34 5.04
2.46M
89.37M
US$ 632.740M
US$ 2.06
0.26 14.44
14.49M
304.78M
US$ 627.850M
US$ 11.50
0.47 4.26
1.12M
54.42M
US$ 625.830M
US$ 2.34
0.08 3.54
2.66M
266.12M
US$ 622.720M
US$ 8.96
4.27 91.04
55.97M
68.38M
US$ 612.620M
US$ 8.94
0.69 8.36
902,550
68.25M
US$ 610.160M
US$ 15.04
-0.07 -0.46
713,808
40.51M
US$ 609.270M
US$ 11.27
0.44 4.06
200,876
53.60M
US$ 604.070M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 11.14
0.26 2.39
460,464
52.97M
US$ 590.090M
US$ 2.84
-0.04 -1.39
6.65M
204.94M
US$ 582.030M
US$ 7.79
0.10 1.30
1.07M
73.33M
US$ 571.240M
US$ 9.13
0.01 0.11
1.22M
62.42M
US$ 569.890M
US$ 4.49
0.20 4.66
141,464
126.19M
US$ 566.590M
US$ 3.36
0.12 3.70
1.75M
167.38M
US$ 562.400M
US$ 18.85
0.28 1.51
361,558
29.60M
US$ 557.960M
US$ 11.25
0.48 4.46
285,011
49.17M
US$ 553.160M
US$ 4.86
1.72 54.78
37.77M
111.42M
US$ 541.500M
US$ 8.22
0.12 1.48
2.77M
65.50M
US$ 538.410M
US$ 10.55
0.38 3.74
178,041
50.60M
US$ 533.830M
US$ 9.08
0.34 3.89
364,999
58.23M
US$ 528.730M
US$ 3.41
0.00 0.00
0
153.89M
US$ 524.760M
US$ 6.73
0.16 2.44
756,687
77.76M
US$ 523.320M
US$ 8.19
0.04 0.49
119,999
63.35M
US$ 518.840M
US$ 7.53
0.61 8.82
2.71M
68.71M
US$ 517.390M
US$ 6.09
0.36 6.28
4.65M
84.66M
US$ 515.580M
US$ 6.17
-0.11 -1.75
11,270
81.20M
US$ 501.000M
US$ 9.26
0.43 4.87
1.33M
53.38M
US$ 494.300M
US$ 19.27
0.38 2.01
280,733
25.64M
US$ 494.080M
US$ 13.05
1.27 10.78
185,361
37.13M
US$ 484.550M
US$ 9.61
1.25 14.95
1.92M
49.55M
US$ 476.180M
US$ 5.28
0.16 3.12
2.69M
89.70M
US$ 473.620M
US$ 6.00
0.51 9.29
433,120
78.15M
US$ 468.900M
US$ 12.66
0.33 2.68
195,554
36.58M
US$ 463.100M
US$ 4.28
0.77 21.94
9.15M
107.42M
US$ 459.760M
US$ 5.33
0.28 5.54
708,866
85.69M
US$ 456.730M
US$ 19.00
0.20 1.06
908
23.94M
US$ 454.860M
US$ 10.21
-0.31 -2.95
837,736
44.40M
US$ 453.320M
US$ 1.60
0.03 1.91
1.72M
282.73M
US$ 452.370M
US$ 5.38
0.03 0.56
2.56M
83.94M
US$ 451.600M
US$ 5.21
0.15 2.96
734,267
84.69M
US$ 441.230M
US$ 16.84
-0.41 -2.38
402,093
26.05M
US$ 438.680M
US$ 1.48
0.14 10.45
3.69M
292.87M
US$ 433.450M
US$ 6.03
-0.15 -2.43
376,979
71.40M
US$ 430.540M
US$ 2.74
0.27 10.93
2.20M
155.15M
US$ 425.110M
US$ 6.85
0.07 1.03
756,670
61.17M
US$ 419.010M
US$ 2.44
0.06 2.52
787,084
171.62M
US$ 418.750M
US$ 2.66
-0.04 -1.48
214,913
153.83M
US$ 409.190M
US$ 8.55
0.05 0.59
281,570
47.55M
US$ 406.550M
US$ 2.41
-0.07 -2.82
4.66M
167.80M
US$ 404.400M
US$ 5.62
0.16 2.93
3.83M
71.12M
US$ 399.690M
US$ 7.25
0.14 1.97
375,500
53.94M
US$ 391.060M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 11.37
-0.49 -4.13
171,647
33.42M
US$ 379.990M
US$ 21.49
0.44 2.09
180,620
17.61M
US$ 378.440M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 16.00
0.83 5.47
65,479
23.22M
US$ 371.520M
US$ 10.17
-0.01 -0.10
1.05M
36.53M
US$ 371.510M
US$ 8.25
0.31 3.85
99,519
43.64M
US$ 359.860M
US$ 3.67
0.23 6.69
664,892
96.69M
US$ 354.850M
US$ 0.27
0.02 5.98
37.71M
1.32B
US$ 351.120M
US$ 3.03
0.19 6.69
3.21M
114.86M
US$ 348.030M
US$ 12.79
0.88 7.39
535,130
27.09M
US$ 346.480M
US$ 7.59
0.36 4.98
1.46M
45.20M
US$ 343.070M
US$ 2.65
0.03 1.15
6.61M
128.67M
US$ 340.980M
US$ 2.39
0.22 10.14
1.46M
141.84M
US$ 339.000M
US$ 4.46
0.25 5.94
985,979
74.24M
US$ 331.110M
US$ 6.50
0.39 6.38
175,442
49.95M
US$ 324.680M
US$ 3.56
-0.01 -0.28
2.19M
91.18M
US$ 324.600M
US$ 21.83
-1.09 -4.76
217,029
14.85M
US$ 324.180M
US$ 7.88
0.00 0.00
3.54M
40.88M
US$ 322.130M
US$ 2.10
0.10 5.00
1.71M
152.10M
US$ 319.410M
US$ 2.98
0.21 7.58
5.59M
106.34M
US$ 316.890M
US$ 7.38
2.24 43.58
19.85M
42.20M
US$ 311.440M
US$ 8.32
0.20 2.46
90,873
37.42M
US$ 311.330M
US$ 1.06
0.11 11.24
8.01M
291.32M
US$ 308.800M
US$ 5.01
0.39 8.44
451,538
61.44M
US$ 307.810M
US$ 1.33
0.07 5.56
1.43M
226.60M
US$ 301.380M
US$ 1.42
0.13 10.08
3.46M
209.67M
US$ 297.730M
US$ 25.25
0.25 1.00
34,026
11.78M
US$ 297.440M
US$ 6.74
0.26 4.01
935,638
43.59M
US$ 293.800M
US$ 5.39
0.33 6.52
1.22M
53.81M
US$ 290.040M
US$ 7.26
-0.04 -0.48
3,596
39.63M
US$ 287.520M
US$ 6.42
0.24 3.88
1.69M
44.51M
US$ 285.750M
US$ 11.04
1.70 18.20
99,736
25.73M
US$ 283.930M
US$ 3.89
3.77 3.00
488,694
72.48M
US$ 281.950M
US$ 1.51
0.13 9.42
4.39M
185.72M
US$ 280.440M
US$ 0.77
0.05 6.97
6.30M
361.49M
US$ 277.260M
US$ 2.60
0.05 1.96
2.24M
106.59M
US$ 277.130M
US$ 25.22
1.17 4.86
193,714
10.95M
US$ 276.160M
US$ 1.86
0.08 4.49
93,664
145.46M
US$ 270.560M
US$ 6.05
0.50 9.01
1.13M
44.48M
US$ 269.100M
US$ 4.61
0.22 5.01
496,603
58.31M
US$ 268.810M
US$ 3.18
0.00 0.00
537,030
84.46M
US$ 268.580M
US$ 5.95
-0.005 -0.08
24,061
44.54M
US$ 264.790M
US$ 3.88
0.26 7.18
1.19M
66.52M
US$ 258.100M
US$ 4.99
0.00 0.00
0
51.59M
US$ 257.430M
US$ 4.43
0.12 2.78
882,176
57.94M
US$ 256.670M
US$ 3.99
0.00 0.00
437,081
64.24M
US$ 256.320M
US$ 3.91
0.00 0.00
765,217
64.26M
US$ 251.260M
US$ 4.46
0.34 8.25
79,425
55.59M
US$ 247.930M
US$ 1.21
0.05 4.31
5.26M
197.04M
US$ 238.420M
US$ 5.27
0.17 3.33
100,009
44.79M
US$ 236.040M
C$ 3.35
0.30 9.84
254,574
70.31M
C$ 235.540M
US$ 21.60
-0.07 -0.32
39,668
10.79M
US$ 233.060M
US$ 8.43
0.53 6.71
121,138
27.43M
US$ 231.230M
US$ 2.27
0.00 0.00
0
100.33M
US$ 227.750M
US$ 4.01
0.01 0.25
117,702
56.62M
US$ 227.050M
US$ 37.11
-0.91 -2.39
29,323
6.10M
US$ 226.370M
US$ 4.71
0.12 2.61
8,061
47.40M
US$ 223.250M
US$ 4.22
0.30 7.65
355,686
52.62M
US$ 222.060M
US$ 4.75
0.19 4.17
1.37M
46.03M
US$ 218.640M
US$ 3.77
0.47 14.24
1.04M
57.95M
US$ 218.470M
US$ 1.65
0.29 21.40
4.82M
131.16M
US$ 216.550M
US$ 32.89
2.56 8.44
336,316
6.53M
US$ 214.770M
US$ 3.02
0.21 7.47
77,363
70.10M
US$ 211.700M
US$ 4.20
0.09 2.19
629,943
50.04M
US$ 210.170M
US$ 2.64
0.24 10.00
3.42M
78.26M
US$ 206.610M
US$ 4.27
0.00 0.00
0
48.13M
US$ 205.520M
US$ 1.91
0.12 6.70
341,688
105.91M
US$ 202.290M
US$ 2.04
0.31 17.92
459,580
98.94M
US$ 201.840M
US$ 13.92
1.03 7.99
75,228
14.48M
US$ 201.560M
US$ 4.35
0.44 11.25
671,449
46.23M
US$ 201.100M
US$ 4.03
-0.27 -6.18
5,952
49.91M
US$ 200.890M
US$ 2.45
0.16 6.99
1.68M
81.50M
US$ 199.680M
US$ 3.59
0.24 7.16
979,270
54.41M
US$ 195.330M
US$ 7.00
-0.23 -3.18
717
27.86M
US$ 195.020M
US$ 3.54
0.24 7.27
935,926
54.63M
US$ 193.390M
US$ 27.61
0.05 0.18
19,948
6.99M
US$ 192.990M
US$ 2.37
0.11 4.87
692,921
81.38M
US$ 192.870M
US$ 4.77
0.25 5.42
50,066
40.44M
US$ 192.700M
C$ 5.31
-0.18 -3.28
16,900
35.62M
C$ 189.140M
US$ 3.61
0.20 5.72
252,244
52.36M
US$ 188.760M
US$ 9.07
0.52 6.02
41,023
20.52M
US$ 186.010M
US$ 3.08
0.10 3.36
197,528
59.74M
US$ 184.000M
US$ 3.72
0.08 2.20
503,878
49.09M
US$ 182.610M
US$ 1.60
0.26 19.40
4.69M
113.89M
US$ 182.220M
US$ 1.50
0.12 8.70
1.44M
121.01M
US$ 181.520M
US$ 4.54
0.29 6.82
1.59M
39.95M
US$ 181.370M
US$ 2.17
0.06 2.84
9,575
82.78M
US$ 179.630M
US$ 8.90
0.08 0.91
824,261
19.99M
US$ 177.910M
US$ 4.14
0.05 1.22
123,954
42.76M
US$ 177.030M
US$ 8.96
-0.13 -1.43
36,664
19.53M
US$ 174.990M
US$ 2.35
-0.01 -0.42
229,116
74.11M
US$ 174.160M
US$ 2.46
0.21 9.33
3.50M
70.71M
US$ 173.950M
US$ 2.68
0.22 8.94
1.23M
63.81M
US$ 171.010M
US$ 8.85
-0.12 -1.34
125,678
19.32M
US$ 170.980M
US$ 5.56
0.78 16.32
3.09M
30.67M
US$ 170.530M
US$ 7.62
0.27 3.67
415,951
22.17M
US$ 168.940M
US$ 1.04
0.23 28.38
1.77M
161.56M
US$ 168.020M
US$ 11.35
0.16 1.43
53,668
14.65M
US$ 166.280M
US$ 1.53
-0.03 -1.92
711,986
107.02M
US$ 163.740M
US$ 4.45
0.01 0.23
309,715
35.85M
US$ 159.530M
US$ 2.66
0.21 8.57
669,507
59.55M
US$ 158.400M
US$ 7.47
0.26 3.61
118,959
21.19M
US$ 158.290M
US$ 1.91
0.11 6.11
2.47M
82.55M
US$ 157.670M
US$ 1.74
0.03 1.75
236,672
89.54M
US$ 155.800M
US$ 3.44
0.10 2.99
89,433
44.20M
US$ 152.050M
US$ 0.68
0.02 2.74
3.50M
220.42M
US$ 148.780M
US$ 1.43
0.02 1.42
221,181
103.82M
US$ 148.460M
US$ 3.39
0.45 15.31
530,727
43.17M
US$ 146.350M
US$ 2.58
0.09 3.61
1.67M
56.59M
US$ 146.000M
US$ 1.49
0.08 5.67
715,025
97.93M
US$ 145.920M
US$ 9.38
-0.29 -3.00
85,039
15.53M
US$ 145.590M
US$ 1.42
-0.02 -1.60
75,125
100.09M
US$ 141.830M
US$ 5.95
0.79 15.31
2.54M
23.61M
US$ 140.480M
US$ 3.80
0.24 6.74
1,594
36.86M
US$ 140.030M
US$ 14.59
2.24 18.14
268,701
9.37M
US$ 136.710M
US$ 2.50
-0.06 -2.34
2.55M
54.52M
US$ 136.300M
US$ 1.96
0.00 0.00
190,619
69.36M
US$ 135.950M
US$ 4.07
0.80 24.46
1.93M
33.08M
US$ 134.640M
US$ 1.90
0.06 3.26
616,347
70.57M
US$ 134.080M
US$ 3.83
0.30 8.50
251,782
34.39M
US$ 131.710M
US$ 9.66
0.23 2.44
34,621
13.14M
US$ 126.930M
US$ 2.28
0.10 4.59
268,416
54.92M
US$ 125.220M
US$ 3.31
0.26 8.52
292,599
37.82M
US$ 125.180M
US$ 0.68
0.0012 0.18
2.04M
184.46M
US$ 124.690M
US$ 0.96
0.17 22.11
978,671
127.97M
US$ 122.980M
C$ 1.86
0.04 2.20
11,000
64.94M
C$ 120.790M
US$ 2.45
0.27 12.39
2.31M
48.88M
US$ 119.760M
US$ 0.99
0.06 6.91
1.17M
119.62M
US$ 118.300M
US$ 1.58
0.06 3.95
651,633
73.63M
US$ 116.340M
US$ 3.34
0.21 6.73
363,840
34.32M
US$ 114.460M
US$ 1.26
0.17 15.60
2.00M
90.55M
US$ 114.090M
US$ 1.62
-0.01 -0.61
2.43M
70.38M
US$ 114.020M
US$ 0.90
0.04 4.68
655,067
125.80M
US$ 113.220M
US$ 9.23
0.43 4.89
143,409
12.18M
US$ 112.420M
US$ 1.78
0.33 22.76
1.92M
62.76M
US$ 111.710M
US$ 0.53
0.04 7.72
5.87M
208.65M
US$ 110.580M
US$ 1.52
0.06 4.11
839,652
71.27M
US$ 108.330M
US$ 1.60
0.10 6.67
188,903
65.88M
US$ 105.410M
US$ 2.19
0.07 3.30
1.07M
48.11M
US$ 105.360M
US$ 16.24
0.43 2.72
10,717
6.36M
US$ 103.290M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 1.63
0.02 1.24
752,283
60.85M
US$ 99.190M
US$ 1.99
0.03 1.53
99,906
49.81M
US$ 99.120M
US$ 5.88
0.11 1.91
35,325
16.71M
US$ 98.250M
US$ 0.77
0.03 3.64
229,323
125.56M
US$ 96.560M
US$ 1.99
0.05 2.58
402,208
48.10M
US$ 95.720M
US$ 0.83
0.02 3.02
1.89M
115.21M
US$ 95.620M
US$ 2.93
0.09 3.27
84,982
32.20M
US$ 94.440M
US$ 6.89
0.39 6.00
11,901
13.70M
US$ 94.390M
US$ 1.86
0.33 21.57
289,726
49.63M
US$ 92.310M
US$ 1.73
-0.01 -0.57
544,467
53.33M
US$ 92.260M
US$ 0.41
0.0095 2.40
844,818
227.48M
US$ 92.130M
US$ 4.75
0.62 15.01
63,864
19.05M
US$ 90.490M
US$ 2.24
0.09 4.19
88,816
40.31M
US$ 90.290M
US$ 6.01
0.31 5.44
388,402
15.00M
US$ 90.150M
US$ 2.47
0.02 0.82
1.25M
36.24M
US$ 89.510M
US$ 2.56
0.03 1.19
129,111
34.54M
US$ 88.420M
US$ 2.90
0.04 1.40
32,551
30.48M
US$ 88.390M
US$ 1.80
0.12 7.14
209,973
49.09M
US$ 88.360M
US$ 1.98
0.21 11.86
70,878
44.27M
US$ 87.650M
US$ 7.76
0.50 6.89
27,612
11.11M
US$ 86.210M
US$ 7.78
0.31 4.15
38,997
10.79M
US$ 83.950M
US$ 1.32
0.02 1.54
236,327
62.76M
US$ 82.840M
US$ 1.26
0.11 9.57
771,076
65.29M
US$ 82.270M
US$ 2.27
0.15 7.08
1.16M
36.10M
US$ 81.950M
US$ 1.35
0.11 8.87
633,592
59.47M
US$ 80.280M
US$ 0.75
-0.0085 -1.11
2.24M
103.80M
US$ 78.270M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 2.07
0.06 2.99
69,945
36.83M
US$ 76.240M
US$ 1.71
0.00 0.00
154,656
44.39M
US$ 75.910M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 2.43
0.28 13.02
340,393
30.34M
US$ 73.730M
US$ 1.58
-0.12 -7.06
300
46.60M
US$ 73.630M
US$ 4.00
-0.23 -5.39
3,713
18.29M
US$ 73.200M
US$ 8.89
0.13 1.48
7,853
8.19M
US$ 72.810M
US$ 0.28
-0.0029 -1.01
888,216
255.88M
US$ 72.410M
US$ 11.32
0.97 9.37
18,395
6.39M
US$ 72.330M
US$ 1.20
0.13 12.15
407,173
60.08M
US$ 72.100M
US$ 1.97
0.01 0.51
6,989
36.18M
US$ 71.270M
US$ 0.79
0.02 1.95
2.45M
90.08M
US$ 70.980M
C$ 0.90
0.03 3.45
2,500
78.16M
C$ 70.340M
US$ 0.85
0.02 2.88
1.04M
82.46M
US$ 69.930M
US$ 1.42
0.03 2.16
7,171
49.05M
US$ 69.650M
US$ 2.57
0.19 7.98
244,204
26.97M
US$ 69.310M
US$ 1.42
0.12 9.23
217,814
48.26M
US$ 68.530M
US$ 1.81
0.15 9.04
499,581
37.42M
US$ 67.730M
US$ 1.68
0.00 0.00
9,312
40.30M
US$ 67.700M
US$ 2.18
0.13 6.34
757,034
31.05M
US$ 67.690M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 2.36
-0.01 -0.42
86,450
27.84M
US$ 65.700M
C$ 2.37
0.02 0.85
5,040
27.40M
C$ 64.940M
C$ 0.57
0.02 3.64
2.65M
113.60M
C$ 64.750M
US$ 1.90
0.04 2.15
48,864
33.84M
US$ 64.300M
US$ 2.15
0.14 6.97
188,005
29.75M
US$ 63.960M
US$ 0.80
0.07 8.93
1.91M
79.97M
US$ 63.580M
C$ 0.85
0.00 0.00
0
74.57M
C$ 63.380M
US$ 1.42
0.19 15.45
1.02M
44.56M
US$ 63.280M
US$ 1.69
0.13 8.33
919,436
37.41M
US$ 63.220M
US$ 7.62
0.08 1.06
93,735
8.25M
US$ 62.860M
US$ 1.48
-0.02 -1.01
131,347
42.51M
US$ 62.700M
US$ 0.76
0.0075 1.00
428,835
82.40M
US$ 62.380M
US$ 17.21
-0.30 -1.71
302
3.55M
US$ 61.100M
US$ 0.79
0.01 1.42
239,570
75.84M
US$ 59.610M
US$ 1.03
0.02 1.88
213,418
57.49M
US$ 59.160M
US$ 2.83
0.41 16.94
357,472
20.80M
US$ 58.860M
US$ 6.53
-0.15 -2.25
3,426
8.91M
US$ 58.160M
US$ 1.83
0.14 8.28
1.69M
31.20M
US$ 57.100M
C$ 0.08
0.00 0.00
0
701.73M
C$ 56.140M
US$ 5.95
0.00 0.00
28,496
9.39M
US$ 55.870M
C$ 0.17
0.005 3.03
60,607
328.48M
C$ 55.840M
US$ 0.61
0.03 4.88
200,104
90.56M
US$ 55.420M
US$ 2.00
0.12 6.38
313,452
27.60M
US$ 55.200M
US$ 1.14
0.08 7.55
191,486
47.74M
US$ 54.420M
US$ 0.62
0.06 10.12
3.55M
85.03M
US$ 52.720M
US$ 0.87
0.0021 0.24
1.80M
60.34M
US$ 52.620M
C$ 0.74
0.03 4.23
66,474
70.89M
C$ 52.460M
US$ 9.00
0.58 6.89
93,585
5.76M
US$ 51.840M
US$ 1.65
-0.09 -5.17
40,435
31.24M
US$ 51.550M
US$ 1.17
-0.02 -1.68
196,595
44.00M
US$ 51.480M
US$ 2.10
0.14 7.14
217,571
24.29M
US$ 51.010M
US$ 1.92
0.03 1.59
228,388
26.53M
US$ 50.940M
US$ 3.03
0.06 1.85
89,834
16.84M
US$ 50.940M
US$ 10.10
0.00 0.00
0
5.02M
US$ 50.700M
US$ 0.97
0.02 2.11
941,891
51.75M
US$ 50.200M
US$ 0.66
0.11 20.38
413,616
75.00M
US$ 49.800M
US$ 0.62
0.08 15.00
3.85M
79.22M
US$ 49.200M
US$ 0.31
-0.0038 -1.21
2.48M
158.72M
US$ 49.040M
US$ 1.50
0.08 5.63
179,348
32.60M
US$ 48.900M
US$ 0.83
-0.02 -2.24
564,376
58.88M
US$ 48.870M
US$ 3.85
0.32 9.07
292,173
12.59M
US$ 48.470M
US$ 4.97
0.00 0.00
0
9.72M
US$ 48.310M
US$ 4.06
0.16 4.10
64,853
11.80M
US$ 47.910M
US$ 0.39
0.02 4.81
2.74M
123.53M
US$ 47.680M
US$ 1.90
0.02 1.06
640,901
24.91M
US$ 47.330M
US$ 1.15
0.02 1.77
2,395
41.08M
US$ 47.240M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 1.79
-0.16 -8.21
1.00M
26.16M
US$ 46.830M
US$ 2.08
0.16 8.33
106,540
22.48M
US$ 46.760M
C$ 0.92
0.00 0.00
0
49.02M
C$ 45.100M
US$ 1.32
0.07 5.60
369,474
34.08M
US$ 44.990M
US$ 3.19
0.14 4.59
627,753
13.80M
US$ 44.020M
US$ 0.79
0.01 1.40
29,411
55.25M
US$ 43.700M
US$ 2.56
-0.01 -0.39
196,659
17.06M
US$ 43.670M
C$ 0.39
0.02 5.41
110,500
111.72M
C$ 43.570M
US$ 1.03
0.05 5.30
191,009
42.18M
US$ 43.450M
US$ 2.00
0.05 2.56
4,022
21.67M
US$ 43.340M
US$ 4.10
-0.23 -5.31
90,392
10.50M
US$ 43.050M
US$ 0.37
0.0052 1.43
1.19M
116.36M
US$ 42.940M
US$ 16.31
-0.36 -2.16
2,857
2.61M
US$ 42.580M
US$ 4.84
0.03 0.62
36,258
8.74M
US$ 42.300M
US$ 5.49
0.36 7.02
301,163
7.67M
US$ 42.110M
US$ 1.35
0.10 8.00
1.11M
31.14M
US$ 42.040M
US$ 1.79
0.07 4.07
236,359
23.23M
US$ 41.580M
C$ 0.31
-0.005 -1.61
734,968
134.53M
C$ 41.030M
US$ 1.17
0.15 14.71
965,879
34.96M
US$ 40.900M
US$ 0.99
0.00 0.00
5,410
40.23M
US$ 39.830M
C$ 0.82
0.04 5.13
11,500
47.65M
C$ 39.070M
US$ 1.92
0.06 3.23
46,899
20.16M
US$ 38.710M
US$ 1.07
0.005 0.47
113,246
36.18M
US$ 38.530M
US$ 0.82
0.02 2.75
360,590
46.58M
US$ 38.290M
US$ 3.14
0.20 6.80
394,787
12.09M
US$ 37.960M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 1.54
0.04 2.67
587,467
23.69M
US$ 36.480M
US$ 2.88
0.02 0.70
32,680
12.65M
US$ 36.430M
US$ 1.69
0.06 3.68
314,495
21.24M
US$ 35.900M
US$ 3.32
-0.11 -3.21
61,015
10.78M
US$ 35.790M
US$ 1.33
0.03 2.31
17,549
26.30M
US$ 34.980M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 2.75
-0.08 -2.83
178
12.54M
US$ 34.480M
US$ 4.25
-0.08 -1.85
82,304
7.98M
US$ 33.920M
US$ 0.96
0.10 11.92
453,792
35.20M
US$ 33.650M
US$ 1.39
-0.01 -0.71
146,373
24.00M
US$ 33.360M
C$ 0.71
0.00 0.00
0
46.03M
C$ 32.680M
US$ 1.23
-0.05 -3.75
6,265
26.47M
US$ 32.610M
US$ 8.89
-0.11 -1.22
48,907
3.65M
US$ 32.450M
C$ 0.43
0.00 0.00
0
74.76M
C$ 32.150M
US$ 4.40
0.02 0.46
18,998
7.30M
US$ 32.120M
US$ 0.69
0.01 1.72
924,641
45.72M
US$ 31.550M
US$ 0.31
0.0079 2.59
461,469
100.77M
US$ 31.540M
US$ 0.58
0.05 10.29
983,150
52.74M
US$ 30.540M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
US$ 2.97
0.01 0.34
32,045
10.14M
US$ 30.120M
US$ 15.45
1.70 12.36
189,006
1.92M
US$ 29.660M
US$ 0.33
0.00 0.00
0
89.34M
US$ 29.390M
US$ 9.64
-0.26 -2.63
6,624
3.04M
US$ 29.310M
US$ 0.99
0.02 2.06
34,497
29.59M
US$ 29.290M
US$ 0.44
0.07 19.26
1.73M
66.79M
US$ 29.120M
US$ 1.86
-0.008 -0.43
3,265
15.49M
US$ 28.840M
US$ 5.65
0.30 5.61
32,406
5.04M
US$ 28.480M
US$ 0.22
0.0004 0.18
969,064
124.54M
US$ 27.900M
US$ 3.20
-0.06 -1.84
53,265
8.70M
US$ 27.840M
US$ 0.36
0.03 8.17
942,783
77.07M
US$ 27.750M
US$ 0.48
0.02 4.44
287,976
58.02M
US$ 27.680M
US$ 8.50
-0.14 -1.62
912
3.25M
US$ 27.620M
US$ 15.10
0.49 3.35
23,891
1.78M
US$ 26.880M
US$ 0.97
0.02 2.11
348,830
27.52M
US$ 26.690M
US$ 4.75
-0.03 -0.63
7,678
5.56M
US$ 26.410M
US$ 1.18
0.01 0.85
115,286
22.30M
US$ 26.310M
US$ 0.42
-0.03 -6.00
238,210
61.77M
US$ 26.130M
US$ 3.62
0.13 3.72
94,510
7.14M
US$ 25.850M
US$ 0.06
0.00 0.00
100
407.29M
US$ 25.250M
US$ 0.84
0.02 1.83
487,153
30.17M
US$ 25.190M
US$ 1.32
0.002 0.15
82,682
18.86M
US$ 24.930M
C$ 0.20
-0.03 -13.33
55,500
127.82M
C$ 24.920M
US$ 7.20
1.15 19.01
259,656
3.46M
US$ 24.910M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 1.78
0.10 5.65
29,469
13.48M
US$ 23.930M
US$ 0.31
0.0056 1.86
212,736
77.45M
US$ 23.780M
US$ 2.05
0.03 1.49
2,093
11.54M
US$ 23.660M
US$ 2.03
-0.02 -0.98
86,508
11.45M
US$ 23.240M
US$ 2.71
0.06 2.08
1,911
8.39M
US$ 22.690M
US$ 0.32
0.0057 1.82
950,904
71.01M
US$ 22.650M
US$ 3.27
0.11 3.48
297,812
6.80M
US$ 22.240M
C$ 0.15
0.00 0.00
0
148.22M
C$ 22.230M
US$ 1.55
0.11 7.64
85,590
14.23M
US$ 22.060M
US$ 1.52
0.03 2.01
127,838
14.35M
US$ 21.810M
C$ 0.04
0.00 0.00
200,831
541.70M
C$ 21.670M
US$ 1.48
0.08 5.71
4.55M
14.50M
US$ 21.460M
US$ 0.97
0.05 5.43
158,924
21.99M
US$ 21.330M
US$ 0.67
-0.03 -4.27
645,140
31.06M
US$ 20.870M
US$ 6.06
0.18 3.06
16,367
3.41M
US$ 20.660M
US$ 1.13
0.02 1.80
41,377
18.06M
US$ 20.410M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 2.37
0.03 1.28
37,982
8.47M
US$ 20.070M
US$ 3.62
-0.10 -2.69
229,617
5.43M
US$ 19.660M
C$ 0.14
0.00 0.00
0
140.03M
C$ 19.600M
US$ 4.11
-0.06 -1.44
56,255
4.75M
US$ 19.520M
US$ 1.08
-0.01 -0.92
200,270
17.77M
US$ 19.190M
US$ 1.00
0.001 0.10
91,764
19.08M
US$ 19.080M
US$ 1.77
0.25 16.45
160,970
10.71M
US$ 18.960M
US$ 0.32
0.01 4.88
589,344
59.12M
US$ 18.920M
US$ 0.56
0.03 5.88
380,309
33.31M
US$ 18.650M
C$ 0.21
0.005 2.44
195,769
88.52M
C$ 18.590M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
US$ 3.84
0.28 7.87
66,933
4.59M
US$ 17.630M
US$ 0.99
-0.0011 -0.11
82,741
17.55M
US$ 17.360M
US$ 3.17
0.05 1.60
38,010
5.35M
US$ 16.960M
US$ 1.63
0.00 0.00
6,076
10.17M
US$ 16.580M
US$ 1.23
0.05 4.24
106,351
13.35M
US$ 16.420M
US$ 0.40
0.06 17.35
385,551
41.49M
US$ 16.390M
C$ 0.12
-0.01 -8.00
15,767
140.64M
C$ 16.170M
US$ 0.48
-0.0028 -0.58
58,741
32.69M
US$ 15.630M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 0.39
-0.0022 -0.56
763,054
38.32M
US$ 15.060M
US$ 0.36
-0.05 -11.54
8.73M
41.27M
US$ 14.900M
US$ 1.54
0.001 0.06
44,386
9.66M
US$ 14.890M
US$ 1.00
0.00 0.00
339,264
14.75M
US$ 14.750M
US$ 2.18
0.03 1.44
14,313
6.66M
US$ 14.530M
US$ 1.21
-0.009 -0.74
8,803
11.70M
US$ 14.170M
US$ 4.36
0.11 2.59
152,335
3.21M
US$ 14.000M
US$ 0.36
0.02 5.51
396,668
38.67M
US$ 13.920M
US$ 0.50
-0.0013 -0.26
111,150
28.01M
US$ 13.860M
US$ 0.38
0.02 4.80
226,075
35.43M
US$ 13.460M
US$ 1.30
0.04 3.17
73,090
10.17M
US$ 13.220M
US$ 1.81
0.02 1.12
7,563
6.99M
US$ 12.650M
C$ 0.03
0.005 20.00
229,165
418.56M
C$ 12.560M
US$ 1.81
0.03 1.40
12,931
6.92M
US$ 12.490M
US$ 0.19
-0.0056 -2.82
58.05M
64.53M
US$ 12.450M
US$ 2.02
0.53 35.70
8.00M
6.15M
US$ 12.440M
US$ 0.32
-0.24 -42.22
1.01M
38.27M
US$ 12.360M
US$ 2.96
0.50 20.33
2.06M
4.17M
US$ 12.340M
US$ 0.30
0.0049 1.69
921,444
41.55M
US$ 12.260M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 0.68
-0.007 -1.02
160,481
16.85M
US$ 11.470M
US$ 0.13
-0.0067 -4.90
95,065
88.13M
US$ 11.460M
US$ 3.61
-0.11 -2.96
3,251
3.12M
US$ 11.260M
C$ 0.04
0.00 0.00
0
280.65M
C$ 11.230M
US$ 6.87
-0.28 -3.92
52,620
1.63M
US$ 11.200M
C$ 0.09
-0.02 -15.00
57,000
129.86M
C$ 11.040M
US$ 1.12
0.03 2.75
274,821
9.44M
US$ 10.570M
US$ 2.17
0.02 0.93
28,175
4.58M
US$ 9.940M
US$ 1.79
-0.04 -2.19
62,478
5.43M
US$ 9.720M
US$ 1.70
0.00 0.00
22,991
5.70M
US$ 9.690M
C$ 0.10
-0.005 -4.76
362,580
96.40M
C$ 9.640M
US$ 8.39
0.01 0.12
12,117
1.12M
US$ 9.400M
US$ 0.99
0.06 6.31
716,144
9.39M
US$ 9.250M
US$ 0.18
-0.002 -1.10
757,442
51.37M
US$ 9.250M
US$ 3.08
-0.01 -0.32
224,519
3.00M
US$ 9.240M
US$ 0.65
0.0043 0.66
76,600
14.09M
US$ 9.190M
US$ 0.35
-0.0046 -1.29
1.70M
25.92M
US$ 9.120M
US$ 1.76
0.01 0.57
2,326
5.17M
US$ 9.100M
US$ 1.30
0.09 7.44
2.79M
6.90M
US$ 8.970M
US$ 0.34
-0.02 -4.71
89,462
25.15M
US$ 8.650M
US$ 3.16
-0.01 -0.32
14,701
2.71M
US$ 8.560M
US$ 0.36
0.01 3.34
345,685
23.13M
US$ 8.370M
US$ 0.19
0.008 4.30
204,569
41.75M
US$ 8.100M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 1.07
-0.05 -4.46
16,294
6.97M
US$ 7.460M
US$ 0.49
0.04 8.14
796,055
15.10M
US$ 7.320M
US$ 0.85
-0.0048 -0.56
100,034
8.47M
US$ 7.210M
US$ 0.86
0.05 5.52
875,047
8.36M
US$ 7.190M
US$ 4.91
0.13 2.72
58,388
1.46M
US$ 7.170M
US$ 6.50
0.00 0.00
0
1.10M
US$ 7.150M
US$ 1.22
0.09 7.96
543,190
5.70M
US$ 6.950M
C$ 0.05
-0.02 -23.08
144,625
137.51M
C$ 6.880M
US$ 1.14
0.06 5.56
130,629
6.03M
US$ 6.870M
US$ 0.35
0.0046 1.32
176,977
19.49M
US$ 6.860M
US$ 2.62
0.005 0.19
17,295
2.58M
US$ 6.750M
US$ 2.92
-0.04 -1.35
224,860
2.30M
US$ 6.720M
US$ 1.10
0.02 1.39
131,409
6.10M
US$ 6.680M
US$ 1.83
-0.13 -6.63
40,247
3.47M
US$ 6.350M
US$ 1.73
0.25 16.89
487,280
3.65M
US$ 6.310M
US$ 2.24
0.16 7.69
542,325
2.76M
US$ 6.180M
C$ 0.02
0.00 0.00
0
308.61M
C$ 6.170M
US$ 0.47
-0.03 -6.47
4.40M
12.85M
US$ 6.040M
US$ 2.70
0.002 0.07
41,649
2.23M
US$ 6.030M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
US$ 1.07
-0.03 -2.73
141,865
5.35M
US$ 5.720M
US$ 11.12
1.51 15.71
196,994
505,798
US$ 5.620M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 0.02
0.00 0.00
0
261.79M
US$ 5.240M
US$ 0.57
-0.02 -3.24
452,521
8.99M
US$ 5.110M
US$ 7.14
-0.08 -1.11
33,375
696,249
US$ 4.970M
US$ 3.04
0.33 12.18
34,892
1.60M
US$ 4.860M
US$ 1.91
0.07 3.80
58,207
2.51M
US$ 4.790M
US$ 0.92
0.04 4.88
512,554
5.09M
US$ 4.680M
US$ 2.96
-0.14 -4.61
953
1.54M
US$ 4.550M
C$ 0.05
0.00 0.00
300,067
90.29M
C$ 4.510M
US$ 2.75
-0.43 -13.52
2,000
1.61M
US$ 4.430M
US$ 3.25
-0.02 -0.61
27,917
1.32M
US$ 4.300M
US$ 0.98
0.008 0.82
11,954
4.34M
US$ 4.250M
US$ 4.64
-0.27 -5.50
80,765
914,234
US$ 4.240M
US$ 0.35
0.0031 0.89
138,653
12.01M
US$ 4.200M
US$ 2.39
0.14 6.00
102,478
1.75M
US$ 4.170M
US$ 0.95
0.0091 0.97
159,801
4.38M
US$ 4.160M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
C$ 0.09
-0.02 -18.18
62,000
44.79M
C$ 4.030M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 3.46
0.04 1.02
4,893
1.09M
US$ 3.770M
US$ 0.85
0.05 6.20
290,059
4.43M
US$ 3.760M
US$ 1.23
0.07 6.03
123,286
3.01M
US$ 3.700M
US$ 0.57
-0.09 -13.26
860,075
6.47M
US$ 3.660M
US$ 2.99
-0.10 -3.24
95,498
1.21M
US$ 3.620M
US$ 1.11
0.01 0.91
28,895
3.23M
US$ 3.590M
US$ 0.24
-0.0002 -0.08
5,854
14.89M
US$ 3.570M
US$ 3.01
0.43 16.67
637,214
1.17M
US$ 3.520M
US$ 0.28
0.0005 0.18
317,703
12.48M
US$ 3.430M
US$ 0.80
-0.05 -5.88
342,811
4.19M
US$ 3.370M
US$ 0.31
-0.008 -2.52
145,004
10.83M
US$ 3.360M
US$ 2.41
-0.28 -10.41
48,950
1.36M
US$ 3.280M
US$ 2.38
0.04 1.71
118,741
1.30M
US$ 3.090M
US$ 0.18
0.00 0.00
0
16.39M
US$ 3.000M
US$ 1.32
-0.06 -4.64
2,859
2.25M
US$ 2.960M
US$ 0.92
0.00 0.00
29,147
3.22M
US$ 2.950M
US$ 1.51
0.00 0.00
31,688
1.93M
US$ 2.910M
US$ 0.59
-0.0027 -0.46
24,219
4.89M
US$ 2.870M
US$ 0.23
0.02 7.55
223
12.27M
US$ 2.800M
US$ 3.75
-0.06 -1.57
3,657
736,431
US$ 2.760M
US$ 0.06
0.0034 5.61
8,284
41.30M
US$ 2.640M
US$ 0.58
-0.06 -9.22
6.17M
4.48M
US$ 2.600M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.53
0.04 7.72
480,987
4.75M
US$ 2.520M
US$ 1.51
0.02 1.34
283,732
1.66M
US$ 2.510M
US$ 1.96
0.03 1.55
11,532
1.28M
US$ 2.510M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 0.28
0.0066 2.41
851,326
8.51M
US$ 2.380M
C$ 0.09
0.005 6.25
88,777
27.30M
C$ 2.320M
US$ 0.36
-0.24 -40.00
7.22M
6.29M
US$ 2.280M
US$ 2.55
-0.70 -21.54
630,285
852,996
US$ 2.180M
US$ 0.67
-0.02 -2.91
783,081
3.19M
US$ 2.140M
US$ 0.30
0.00 0.00
0
7.24M
US$ 2.140M
US$ 2.87
-0.29 -9.18
205,603
724,152
US$ 2.080M
US$ 0.33
0.01 3.33
2.69M
5.90M
US$ 1.920M
US$ 0.003
0.0005 20.00
1.49M
635.88M
US$ 1.910M
US$ 0.69
0.0067 0.98
111,764
2.77M
US$ 1.900M
US$ 0.05
-0.002 -3.70
32,052
36.47M
US$ 1.900M
C$ 0.02
0.00 0.00
0
121.27M
C$ 1.820M
US$ 0.006
-0.0003 -4.76
531,445
302.90M
US$ 1.820M
US$ 1.26
0.01 0.80
77,129
1.30M
US$ 1.640M
US$ 0.66
0.0098 1.52
338,795
2.51M
US$ 1.640M
US$ 0.95
0.02 2.66
806,716
1.60M
US$ 1.510M
US$ 0.73
0.03 3.69
140,078
2.04M
US$ 1.490M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.28
0.00 0.00
0
4.85M
US$ 1.380M
US$ 0.02
0.0003 1.27
26,334
54.39M
US$ 1.310M
US$ 0.46
-0.01 -2.12
1.47M
2.78M
US$ 1.280M
US$ 0.10
0.00 0.00
0
12.23M
US$ 1.250M
C$ 0.03
0.00 0.00
0
38.74M
C$ 1.160M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.89
0.006 0.68
156,973
1.27M
US$ 1.130M
US$ 0.01
0.00 0.00
11
112.91M
US$ 1.130M
US$ 0.74
-0.01 -1.94
49,850
1.44M
US$ 1.060M
US$ 0.07
0.00 0.00
0
14.37M
US$ 1.050M
C$ 0.12
0.02 15.00
1,800
8.86M
C$ 1.020M
US$ 0.30
0.01 3.69
1.48M
3.27M
US$ 984K
US$ 0.02
0.00 0.00
0
47.10M
US$ 942K
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 1.02
-0.03 -2.86
25
863,788
US$ 881K
US$ 0.18
0.00 0.00
0
4.70M
US$ 846K
US$ 0.03
-0.002 -6.67
9,510
29.49M
US$ 826K
US$ 0.19
-0.003 -1.58
11,713
4.31M
US$ 806K
C$ 0.005
-0.005 -50.00
85,889
141.96M
C$ 710K
US$ 0.02
0.00 0.00
34,910
39.74M
US$ 676K
US$ 0.03
0.00 0.00
12,401
26.83M
US$ 671K
US$ 1.15
0.00 0.00
264,508
580,840
US$ 668K
US$ 0.07
0.0045 6.47
11.56M
8.29M
US$ 613K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.20
-0.0001 -0.05
418
2.05M
US$ 410K
US$ 0.05
0.0055 12.94
39,464
6.96M
US$ 334K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.005
0.00 0.00
0
61.76M
US$ 309K
US$ 0.21
0.00 0.00
0
1.39M
US$ 292K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.008
0.00 0.00
796,081
34.87M
US$ 279K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.05
0.01 26.58
291.00M
3.93M
US$ 197K
US$ 0.03
0.00 0.00
0
3.41M
US$ 109K
US$ 0.001
0.0003 42.86
302
100.08M
US$ 100K
US$ 0.001
0.00 0.00
0
18.98M
US$ 19K
US$ 0.002
0.00 0.00
0
4.87M
US$ 10K
US$ 0.07
0.00 0.00
4,113
-
US$ -
US$ 0.10
0.00 0.00
145,142
-
US$ -
US$ 0.00
-0.0001 -100.00
157
44.57M
US$ -
US$ 0.00
-0.0001 -100.00
12,238
54.52M
US$ -
US$ 0.00
0.00 0.00
0
30.74M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
3.14M
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
6.58M
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
-0.0001 -100.00
13
10.88M
US$ -
US$ 0.00
0.00 0.00
0
42.08M
US$ -
US$ 0.00
0.00 0.00
0
71.42M
US$ -
US$ 0.00
-0.0001 -100.00
1.08M
5.12B
US$ -
US$ 0.00
0.00 0.00
0
172.20M
US$ -
US$ 0.00
-0.0001 -100.00
300
514.01M
US$ -
US$ 0.34
-0.01 -2.94
73,427
-
US$ -
US$ 1.39
-0.04 -2.80
44,330
-
US$ -
C$ 1.85
0.00 0.00
0
-
C$ -
US$ 5.59
0.49 9.61
69,964
-
US$ -

Latest Biotechnology Stock News


Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services... Read more


Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases LOS ANGELES / Jun 09, 2025 / Business Wire / Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+... Read more


Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

New Drug Submission filed by Lipocine's licensing partner Verity Pharma Over 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large commercial opportunity SALT LAKE CITY, June 9, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that its licensing partner, Verity... Read more


Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash... Read more


Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical... Read more


PDS Biotechnology to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PRINCETON, N.J., June 09, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and... Read more


Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary Session DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal... Read more


BioRestorative Therapies to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025  ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma  BioRestorative to release new clinical data to the public prior to market open on June 13th  MELVILLE, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the... Read more


Medicus Pharma Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880). The Company, in December... Read more


Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental...

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials... Read more


PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary...

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions. The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections (“SSI”) in patients treated with D-PLEX100 arm versus standard of care (“SoC”) arm (p<0.005). The Company expects to submit a New Drug Application (“NDA”) to... Read more


Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology

Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged... Read more


Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Partici

Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers  Data support planned accelerated approval BLA submission in H2 2026  Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m.... Read more


Collplant Biotechnologies Broadens Its Collaboration With Stemcell Technologies

CollPlant's proprietary rhCollagen to be used in clinical and commercial applications REHOVOT, Israel, June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen)  for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies,... Read more


Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026  Initiated global, confirmatory Phase 3 FORWARD™ study of del-brax 2mg/kg every six weeks  Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET  SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA... Read more


NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome measure of Alzheimer’s disease biomarker in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215), supporting the emerging link between CETP-inhibition and prevention of AD pathology  NewAmsterdam to present results during the AAIC conference in July  NAARDEN, The Netherlands and MIAMI,... Read more


Bio-Path to Present at Life Sciences Virtual Investor Forum

HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will... Read more


Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2

SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, click here. The event will feature key opinion leader (KOL) Neal Bhatia, MD (Director of Clinical Dermatology... Read more


Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long... Read more


IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for n... Read more


Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not... Read more


Ascendis Pharma: TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body pro... Read more


Alnylam Pharmaceuticals Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy  Novel RNAi Mechanism Delivers Rapid Knockdown of Transthyretin (TTR), Addressing the Disease at its Source  Approval Based on HELIOS-B Phase 3 Study, Which Showed Up to 36% Reduction in All-Cause Mortality, With Preservation of Functional Capacity and Quality of Life, with Four Quarterly Doses Per Year  Decision... Read more


Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology

Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its U.S. patent application covering one of its next-generation antibody-drug conjugate (ADC) technologies. The allowance of... Read more


Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating... Read more


Evofem Biosciences’ CEO Saundra Pelletier Joins Aditxt Board of Directors

MOUNTAIN VIEW, Calif. / Jun 09, 2025 / Business Wire / Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt’s Board of Directors. “We believe that Saundra’s background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement... Read more


Regeneron Pharmaceuticals: Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline Results support commitment to enhance clinical understanding of chronic diseases in communities of color TARRYTOWN, N.Y. and PARIS,... Read more


Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue... Read more


Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million

VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) --  Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the closing of its previously announced non-brokered private placement for gross proceeds of $4,905,150 - consisting of $3,555,150 of Units and $1,350,000 of Debenture... Read more


PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m.... Read more


Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and communicated the Agency’s intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pharmaceuticals, Inc. Phathom... Read more


Vertex Pharmaceuticals Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® BOSTON / Jun 06, 2025 / Business Wire / Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)... Read more



Apellis Pharmaceuticals and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observed New data presented at late-breaking session at the European Renal Association Congress Marketing applications for EMPAVELI are under review with the FDA and EMA WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data... Read more


Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha... Read more



Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice’s extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and... Read more


Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was comparable to placebo. EXXUA is expected to serve as a major growth catalyst... Read more


Arcutis Biotherapeutics to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0.05% New data demonstrate that for children ages 2 to 5 who achieved disease clearance and switched to proactive twice-weekly application of investigational ZORYVE cream 0.05%, the median duration of disease control was... Read more


Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Robert Infarinato named VP, Strategic Development Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to treat cancer. Phio announced today a strategic initiative to heighten awareness of potential applications of the broader... Read more


OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric...

If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access NEW YORK / Jun 06, 2025 / Business Wire / OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has... Read more


BioCryst Pharmaceuticals Achieves Reimbursement for ORLADEYO Across all Major European Countries

ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national... Read more


Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced... Read more


Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress...

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European... Read more


Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants proportionately to the amount of non-dilutive capital received, under certain circumstances Financing co-led by new investors Coastlands Capital and Frazier Life Sciences and included participation from Gilead Sciences, Inc., Logos Capital, Samsara BioCapital and... Read more


Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock... Read more


MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

CHICAGO / Jun 05, 2025 / Business Wire / MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®)... Read more


Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM, June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO... Read more


Artelo Biosciences' Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential... Read more


Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner...

Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead... Read more